Overview
- 5 inspections across 5 sites are on record.
- 11 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-03-20.
At a glance
Inspections
5
Sites
5
Observations
11
Career since
Mar 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Bora Pharmaceuticals Injectables Inc | 20 Mar 2026 | Human Drugs | On file |
| Ten23 Health Valais AG | 27 Aug 2025 | Human Drugs | On file |
| Eli Lilly & Company | 20 May 2025 | Human Drugs | On file |
| Amgen Singapore Manufacturing Pte. Ltd. | 14 May 2024 | Human Drugs | On file |
| International Medication Systems Ltd. | 1 Mar 2019 | Human Drugs | On file |
Sites inspected
Bora Pharmaceuticals Injectables IncBaltimore, United States1 insp.
Ten23 Health Valais AGVisp, Switzerland1 insp.
Eli Lilly & CompanyIndianapolis, United States1 insp.
Amgen Singapore Manufacturing Pte. Ltd.Singapore, Singapore1 insp.
International Medication Systems Ltd.South El Monte, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Liqun Zhao2 shared
Hyung-Yul Lee1 shared
Tekalign Wondimu1 shared
Brandy N Lepage1 shared
Zhong Li1 shared
Scott D Mcgrew1 shared
Kara J Wright1 shared
Jacob G Lutz1 shared
Rafeeq A Habeeb1 shared
Jie He1 shared
Full investigator report
Get the verbatim findings behind Sudipan Karmakar's 11 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site